<DOC>
	<DOCNO>NCT00788944</DOCNO>
	<brief_summary>This study determine percentage patient depression treat extended-release venlafaxine HCl ( U.S. market brand Effexor XR速 ) Poor Metabolizers ( base level drug blood ) 2D6 ( system liver breaks medication chemical ) .</brief_summary>
	<brief_title>Determine The Percentage Of Depressed Outpatients Who Do Not Effectively Metabolize Extended-release Venlafaxine HCl</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<criteria>Men woman subject age 18 year old . Current outpatient treatment extendedrelease venlafaxine HCl ( U.S. market brand Effexor XR速 ) , within US Food Drug Administration ( FDA ) approve dosage range depression ( 37.5 mg/day 225 mg/day ) , 8 week less . Ability blood draw within 4 12 hour recent dose Effexor XR速 . Determination investigator blood draw contraindicate . Participation investigational study within past 30 day study medication know . Previous treatment Effexor XR速 extendedrelease venlafaxine HCl ( generic ) 6 month prior current treatment regimen . Treatment DVS SR within last 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>